

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/211489 A1

(51) International Patent Classification:

A61K 31/381 (2006.01) *A61P 25/18* (2006.01)
A61K 45/06 (2006.01) *A61P 25/22* (2006.01)
A61P 25/00 (2006.01) *A61P 25/28* (2006.01)
A61P 25/16 (2006.01) *A61P 25/30* (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR, OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2021/026953

(22) International Filing Date:

13 April 2021 (13.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/009,595 14 April 2020 (14.04.2020) US
63/039,722 16 June 2020 (16.06.2020) US

(71) Applicant: SUNOVION PHARMACEUTICALS INC.

[US/US]; 84 Waterford Drive, Marlborough, Massachusetts
01752 (US).

(72) Inventors: BOWEN, Carrie A.; c/o Sunovion Pharmaceu-

ticals Inc., 84 Waterford Drive, Marlborough, Massachu-
setts 01752 (US). HOPKINS, Seth Cabot; c/o Sunovion
Pharmaceuticals Inc., 84 Waterford Drive, Marlborough,
Massachusetts 01752 (US). SYNAN, Colleen M.; c/o
Sunovion Pharmaceuticals Inc., 84 Waterford Drive, Marl-
borough, Massachusetts 01752 (US).

(74) Agent: FREDERICKS, Kellie S.; Heslin Rothenberg Far-

ley & Mesiti P.C., 5 Columbia Circle, Albany, New York
12203 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: (S)-(4,5-DIHYDRO-7H-THIENO[2,3-C]PYRAN-7-YL)-N-METHYLMETHANAMINE FOR TREATING NEU-
ROLOGICAL AND PSYCHIATRIC DISORDERS

(57) Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizo-
phrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action.
Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with
Compound 1, or a pharmaceutically acceptable salt thereof.

WO 2021/211489 A1